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ABSTRACT 
Background: Opioid analgesics may offer benefits over nonopioids in some 
older patients, especially those with moderate-to-severe pain. Polymer-coated 
extended-release morphine sulfate (P-ERMS) has been found to be efficacious 
and well tolerated in patients with chronic, moderate-to-severe, nonmalignant 
pain when used QD or BID. 
Objective: The purpose of this analysis was to determine the effectiveness of
P-ERMS in older patients (aged >65 years) with persistent, moderate-to-severe, 
inadequately controlled, nonmalignant pain. 
Methods: This was a subgroup analysis of the older population from an open- 
label trial in community-based pain clinics in which patients underwent treatment 
with P-ERMS for persistent, moderate-to-severe, inadequately controlled, nonma- 
lignant pain ~4 on a scale of 0-10). Patients received P-ERMS at a dose determined 
by the investigator based on their previous analgesic regimen, QD (morning or 
evening) for a 4-week treatment period. Dose increases were permitted after weeks 
1 and 2; switching to BID was allowed after week 2, if needed. Measurements 
included changes in pain and sleep scores (0-10 scale), quality of life (QOL) scores 
(physical and mental component summaries [PCS and MCS, respectively] of the 
36-Item Short-Form Health Survey instrument), and patient and clinician assess- 
ments of current reatment based on a 9-point scale ranging from --4 to +4. 
Results: One hundred forty-eight older patients (mean [SD] age, 73.4 [5.5] years) 
began treatment with P-ERMS; 86 (58.1%) of those patients completed the study. 
Pain and sleep scores significantly improved (decreased) from baseline to week 4 
(7.4 vs 5.0 and 5.0 vs 3.2, respectively; both, P < 0.001). PCS and MCS scores signif- 
icantly improved (increased) from baseline (27.7 vs 31.6 and 37.6 vs 40.8, respec- 
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tively; both, P < 0.05), as did patient and clinician global assessments (-1.2 vs 
1.1 and -1.5 vs 1.4; both, P < 0.001). Results found in these older patients were 
similar to those observed in the younger patients (aged <65 years). A majority 
(71.4%) of the older patients remained on QD administration and took signifi- 
cantly lower mean daily doses than younger patients (77.0 vs 105.2 mg/d, respec- 
tively; P = 0.001). The dropout rate for the subgroup was 41.1%, which was simi- 
lar to that reported in previous studies in mixed-age populations taking other 
extended-release morphine formulations. Of the patients who discontinued (n = 
60), adverse vents (AEs) were the most prevalent reason (n = 29). The most com- 
mon treatment-related AEs were constipation (19.6%) and nausea (9.5%). 
Conclusions: This subgroup analysis of a previously published study 
revealed that the older patients in that study who were receiving P-ERMS for 
persistent, moderate-to-severe, inadequately controlled, nonmalignant pain 
who completed the study attained significant improvements in pain, sleep, and 
QOL scores compared with baseline. Patient and clinician satisfaction with 
treatment increased significantly from baseline to study end. Older patients uti- 
lized significantly lower mean daily doses than younger patients (P < 0.001), and 
>70% remained on a QD administration regimen for the duration of the study. 
(Curr Ther Res Clin Exp. 2007;68:137-150) Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Persistent pain, which continues for a prolonged period of time and may or may 
not be associated with a recognizable disease process, is common in the older 
population (aged >65 years). 1Approximately 25% to 60% of the community- 
dwelling older population and 45% to 80% of older nursing home residents have 
persistent pain, 1-3 which is often suboptimally diagnosed and managed. 3,4 
American Geriatrics Society (AGS) guidelines I for pain management recog- 
nize the usefulness of nonopioid and opioid analgesics in managing persistent 
pain. The recommended progression in most cases is from nonopioid anal- 
gesics such as acetaminophen to anti-inflammatory drugs, neurotransmitter- 
modulating and membrane-stabilizing drugs, and opioids. 1 Acetaminophen is 
indicated for mild-to-moderate pain; however, it has a ceiling dose and must be 
used with caution in those patients with reduced renal or hepatic function. 1
While traditional NSAID treatment might be beneficial in some patients, the risk 
for gastrointestinal bleeding is of concern. 1 Cyclooxygenase-2 (COX-2) in- 
hibitors are considered to offer a more tolerable gastrointestinal profile than 
nonselective COX inhibitors; however, studies have documented an increased 
risk for cardiovascular complications in patients receiving certain COX-2 
inhibitors. 5,6 The US Food and Drug Administration recommends COX-2 
inhibitors only for selected patients who are not candidates for nonselective 
NSAIDs. 7 They have also issued supplemental request letters to prescription 
NSAIDs sponsors, including celecoxib, to revise their labeling to include a 
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boxed warning highlighting the potential for increased risk for cardiovascular 
events and gastrointestinal b eeding. 8 Finally, certain adjuvant medications, 
including certain antiepileptic drugs and duloxetine, have indications for neu- 
ropathic pain 9-12 and might be used alone or in combination with other anal- 
gesics if the risk for side effects or drug-drug interactions i considered. 1 
Opioid analgesics may benefit some older patients, especially those with 
moderate-to-severe pain who have contraindications to long-term daily use of 
NSAIDs. 1 The potential effects of aging must be considered when prescribing opi- 
oids. Reduced rates of systemic learance 13,14 and reduction in volume of distri- 
bution can yield increased initial plasma concentrations, 13 while physiologic and 
neurologic hanges might increase the older patient's ensitivity to opioids. 15 
Special precautions, including dose reduction, must be used in patients with 
concurrent renal or hepatic disease, due to potential variations in drug clear- 
ance and potential accumulation of active metabolites. 16While age-related 
changes in drug disposition may lead to concern over adverse events (AEs), 1T 
they might also yield increased clinical response on lower doses of opioids. 18,19 
AGS guidelines recommend long-acting or sustained-release opioids to 
relieve continuous moderate-to-severe pain. 1 Studies have examined the use of 
opioids in older patients with cancer-related persistent pain. 14,19,2° An English- 
language literature search of MEDLINE (1996 to February 2007) and EMBASE 
(1974 to February 2007) was conducted using the following key terms: pain, 
analgesics-opioid, chronic or persistent pain, elder or old, aged, long-acting, 
delayed-action, and controlled-, time-, sustained-, prolonged- or extended-release. 
The literature search revealed no specific studies on the use of extended- 
release opioids in older patients with nonmalignant persistent pain. One ret- 
rospective study of analgesics in an elderly nursing home population (n = 
10,372) did indicate that the residents had attained benefits in functional sta- 
tus (adjusted hazard ratio [AHR] = 1.85; 95% CI, 1.05-3.23) and social engage- 
ment (AHR = 1.58; 95% CI, 0.99-2.50) while taking long-acting opioids. 21 
Challenges exist in study design and recruitment of older patients for clinical 
trials. 22 
Polymer-coated extended-release morphine sulfate* (P-ERMS) is a capsule 
formulation of extended-release morphine sulfate indicated for the treatment 
of moderate-to-severe chronic pain. 23 Its pellets are a pH-dependent, polymer- 
coated formulation that facilitates the release of morphine primarily in the alka- 
line environment of the intestine, yielding effective plasma morphine concentra- 
tions with a relatively small degree of fluctuation for up to 24 hours. 24 The 
bioavailability of P-ERMS is not affected by food. 2s For these reasons, P-ERMS is 
indicated for either QD or BID administration, 23 and can be administered without 
regard to meals. The capsules can be administered orally, or can be opened so 
the pellets contained in the capsules can be sprinkled on apple sauce or admin- 
istered via gastric feeding tube. 23 
*Trademark: KADIAN ® (Alpharma Pharmaceuticals LLC, Piscataway, New Jersey). 
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The current analysis examined the effectiveness of P-ERMS in treating older 
patients, aged >65 years, who had unsatisfactory control of chronic, moderate- 
to-severe, nonmalignant pain with prior medication and participated in a previ- 
ously published, large, open-label, community-based trial using P-ERMS. 26 That 
trial found that P-ERMS is efficacious and well tolerated in patients with chronic, 
moderate-to-severe, nonmalignant pain when used QD or BID. 
METHODS 
Patients and Study Protocol 
The KADIAN~: Response Of Non-malignant, Under-treated Subjects with 
Moderate/Severe Pain (KRONUS-MSP) trial was a community-based, prospec- 
tive, open-label trial involving patients attending 1of 202 study sites through- 
out the United States.  26 Participants were men and women aged _>18 years who 
had persistent, moderate-to-severe, nonmalignant pain conditions for which 
treatment with an extended-release opioid was warranted. They were required 
to have had unsatisfactory esponse on their previous treatment regimen, as 
indicated by pain intensity of _>4 on a scale of 0 (no pain) to 10 (worst pain imag- 
inable). Patients with hypersensitivity o opioids, conditions that might con- 
traindicate treatment with morphine, including gastrointestinal and respiratory 
conditions that might be worsened by opioid treatment, or who had a history 
of clinically significant laboratory abnormalities that might affect their safe par- 
ticipation in the study, were excluded. 
The protocol, informed consent form, site regulatory package, and patient infor- 
mation were reviewed by IRB Company, Inc., Laguna Hills, California. The protocol 
was designed to ensure adherence to International Conference on Harmonisation 
Guidelines for Good Clinical Practice, 27 Code of Federal Regulations Title 21, parts 
50, 56, and 312 D, 28 and the Declaration of Helsinki. 29 No patient could enter the 
study until written informed consent was obtained either from the patient or from 
a legally appointed representative. 
The study protocol was described in detail in a previous publication. 26 
Patients were randomized to receive P-ERMS in the morning (hM administra- 
tion) or evening (PM administration). Investigators determined initial daily 
dose based on each patient's individual factors and pre-study analgesic regi- 
men. Instructions to investigators included the suggestion that the starting 
dose of P-ERMS be reduced 50% from the equianalgesic dose of pre-study 
medication. After week 1, patients were queried for pain relief and rescue 
medication use, and the investigator could increase the dose if needed. After 
week 2, investigators could increase the dose for patients who had not yet 
increased their dose if needed; patients who had already increased their dose 
could be switched to a BID regimen. Immediate-release morphine was pre- 
scribed for breakthrough pain. No other opioids were allowed during the 
study period. Analgesics and other adjuvant medications such as acetamino- 
phen, NSAIDs, corticosteroids, neuroleptics, anxiolytics, or antidepressants 
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were permitted only if the dose was anticipated to remain stable for the dura- 
tion of the study. 
The present study compared the results of patients aged >65 years with 
those of the remaining study population aged <65 years. 
End Points 
Effectiveness was assessed by determining the change from baseline to 
study end in pain, sleep interference, quality of life (QOL), and patient and cli- 
nician global assessments of treatment. Investigators were provided with stan- 
dard question cards containing the visual numeric scale (VNS) to attain a uni- 
formity of response. 
Pain was assessed by a VNS score of 0 (no pain) to 10 (worst pain imagina- 
ble), based on the previous 24 hours. A 0 to 10 scale has been recognized as a 
good first-choice scale for measuring pain intensity in most older persons. ~
Similarly, sleep was assessed by a VNS ranging from 0 (pain did not interfere 
with sleep at all) to 10 (pain completely interfered with sleep) during the previ- 
ous 24 hours. Unlike the pain scale requirement of_>4 points, there was no entry 
criterion for the sleep scale 0e, patients with no reported sleep problems were 
allowed to enter the trial). 
QOL assessments were based on the 36-Item Short-Form Health Survey, 
version 2 (SF-36v2¢~; QualityMetric Inc., Lincoln, Rhode Island), a multipurpose 
survey yielding 2 main component scores (physical and mental), 8 subscale 
scores, and a health transition scale rating current health compared with health 
1 year prior. 3° Patients completed this form and sent it directly to the data 
analysis center in Orange, California. 
Patients completed a global assessment of current treatment based on a 
9-point scale ranging from -4 (completely dissatisfied; inadequately controlled 
pain, cannot function, disruptive administration schedule) to +4 (completely 
satisfied; pain controlled, convenient administration schedule, no side effects). 
Similarly, clinicians described their overall satisfaction with the treatment regi- 
men by choosing a number anging from -4 (completely dissatisfied; consider 
change to different drug or drug class) to +4 (completely satisfied; no change to 
drug dose or administration schedule, no side effects). Assessments were com- 
pleted at baseline to describe satisfaction with the prior treatment regimen and 
after 4 weeks of P-ERMS treatment. Patients were then asked to complete an 
additional global assessment of treatment, if they were still receiving P-ERMS, 
4 weeks following the completion of the study by means of a stamped, self- 
addressed business reply card. 
Tolerability 
AEs, whether volunteered by the patient, discovered by investigator ques- 
tioning, or detected through physical examination or other means, were 
recorded on the case report form and assessed and summarized with regard to 
frequency, severity, and relationship to study medication. 
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Analyses 
The safety population consisted of all patients who took _>1 dose of P-ERMS; 
the modified intent-to-treat (mITT) population included all patients in the safety 
population who completed a valid baseline assessment and _>1 post-baseline 
outcome assessment. Statistics after week 4 versus baseline were calculated on 
the mITI" population using the paired t test, conducted against a 2-sided alter- 
native hypothesis with a significance level of P < 0.05. One-way analysis of 
covariance, with baseline as the covariate for week 4 and the change from base- 
line at week 4, was used to compare results in older patients with those of 
patients aged _<65 years, while a 2-sample t test was used to compare adminis- 
tration regimens between age groups. AEs were reported in the safety popula- 
tion. Statistical analyses were performed using SAS software, version 8.2 (SAS 
Institute Inc., Cary, North Carolina). 
RESULTS 
Of the 1428 patients enrolled in the initial study, 1418 took >1 dose of study 
medication (safety population). There were 148 patients aged >66 years (mean 
[SD] age, 73.4 [5.5] years; median age, 73.0 years) who began the study. Five 
patients did not specify age. Of these, 71.5% were women and 89.8% were white. 
Among the younger patients (<65 years; n = 1265), 59% were women and 89.5% 
were white. 
There were 146 older patients for whom disposition was recorded. Among 
the older patients, the most common medical conditions were back pain 
(12.8%), intervertebral disc degeneration ot otherwise specified (NOS) 
(10.8%), spinal stenosis NOS (8.8%), localized osteoarthritis (8.1%), post- 
laminectomy syndrome (6.1%), and spondylosis (6.1%). Seventy-three (50.0%) 
of the older patients enrolled due to pain alone, 8 (5.5%) due to decreased QOL 
alone, and 65 (44.5%) due to pain and decreased QOL. 
Eighty-six (58.9%) older patients completed the study, while 60 (41.1%) dis- 
continued. Reasons for discontinuation were: AE, 29 (19.9%); patient's decision, 
23 (15.8%); lack of effectiveness, 3 (2.1%); noncompliance, 2 (1.4%); and missing/ 
other, 3 (2.1%). Of the 103 older patients in the mITT population, 86 (83.5%) 
completed the study. 
Older patients had statistically significant improvements in all outcomes 
after 4 weeks compared with baseline. The improvements in pain and sleep 
scores (P < 0.001) are shown in Figure 1. 
Older patients recorded statistically significant increases in the QOL indices, 
including 7 of 8 SF-36v2 subscales (~igure 2). A significant improvement was 
also observed in health transition, the 1 scale for which a lower score indicates 
improvement (mean [SD], 3.5 [1.0] vs 3.2 [1.1 ]; P = 0.004). Mean (SD) physical 
component summary (PCS) scores increased significantly from baseline to 
week 4 (27.7 [6.9] vs 31.6 [6.7]; P < 0.001); mean (SD) mental component sum- 
mary scores also increased from baseline (37.6 [12.2] vs 40.8 [12.0]; P= 0.011). 
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!-'1 Week 4 
Pain 
Sleep 
n = 103' 
n =91" 
t 
n = 102" 
n = 89* 
7.4 -~ 32.7% Improvement 
5.0 -~ 34.9% Improvement 
I I I 
0 2 4 6 8 10 
Pain Scale 
Figure 1. Mean pain and sleep assessment scores on a scale of 0 to 10 (with 0 = no 
pain; pain did not interfere with sleep at all to 10 = worst pain imaginable; 
pain completely interferes with sleep) at baseline and 4 weeks in older 
patients with persistent moderate-to-severe pain receiving polymer-coated 
extended-release morphine sulfate capsules. *Based on the number of 
respondents to each question, tp < 0.001 versus baseline. 
As in the original study population, the change in PCS scores in the subgroup 
also reached clinical relevance. 26
Older patients and their clinicians expressed improved satisfaction with pain 
treatment after 4 weeks, as measured by the global assessment scores shown in 
Figure 3. Mean patient assessment scores improved from-1.2 at baseline to 
+1.1 at 4 weeks (P < 0.001). Mean clinician assessment scores improved from 
-1.5 at baseline to + 1.4 at 4 weeks (P < 0.001). 
Of the 86 older patients who completed the study on P-ERMS, 63 (73.3%) 
returned the business reply card 4 weeks later. Of these patients, 38 (60.3%) 
remained on P-ERMS after the study and 25 (39.7%) were not taking P-ERMS. 
The improvements in pain and sleep, QOL, and patient and clinician global 
assessment scores were comparable to those seen in patients <65 years. 
Older patients had significantly lower initial and final doses than younger 
patients (initial, P < 0.001; final, P = 0.001). The mean (SD) initial dose for older 
patients was 40.5 (34.1) mg/d (median, 20.0 mg). At the last administration 
adjustment following week 2, the mean (SD) dose was 77.0 (76.9) mg/d (median, 
55.0 mg). Patients aged <65 years used a mean (SD) daily initial dose of 
59.6 (54.3) mg (median, 50.0 mg) and a mean (SD) daily dose, after final adjust- 
ment, of 105.2 (97.8) mg (median, 80.0 mg). 
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Figure 2. Mean scores from the 36-Item Short-Form Health Survey; version 2 (scale 0 -  
100) reported at baseline and 4 weeks by older patients with persistent mod- 
erate-to-severe pain receiving polymer-coated extended-release morphine 
sulfate capsules. PCS = Physical Component Summary; MCS = Mental 
Component Summary. *P < 0.001 versus baseline; tp < 0.05 versus baseline; 
~Based on the number of respondents to each question; §P < 0.01 versus 
baseline. 
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Figure 3. Patient and clinician global assessment scores. *P < 0.001 versus baseline; 
tBased on the number of respondents to each question; ~Patients receiving 
polymer-coated extended-release morphine sulfate who provided a patient 
global assessment score on the business reply card. 
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A majority (71.4%) of the older patients remained on QD administration 
throughout the study. This proportion was significantly higher than that of the 
younger patients (55.6%; P = 0.004). The remaining patients were on BID admini- 
stration. After the final dose adjustment, he mean (SD) total daily dose was 
lower in older patients receiving P-ERMS QD compared with those receiving it 
BID (58.5 [48.8] mg vs 127.3 [110.5] mg, respectively). 
Treatment-related AEs affecting >5% of the older population were constipation 
(29 [19.6%] patients), nausea (14 [9.5%]), dizziness (11 [7.4%]), sedation (10 
[6.8%]), and somnolence (9 [6.1%]). There was no significant difference in the 
overall rate of AEs in patients who ended the study on QD administration versus 
those receiving BID administration (41.5% vs 38.5%); there were also 
no significant differences in the rate of individual AFt. Sixty (41.1%) patients dis- 
continued the study. Twenty-nine (48.3%) discontinued the study due to an AE. 
The most common AEs causing discontinuation were constipation (11 [18.3%] pa- 
tients) and nausea (7 [11.7%]). Other reasons for discontinuation were patient 
decision (23 [38.3%] patients), lack of effectiveness (3 [5.0%]), noncompliance 
(2 [3.3%]), and other (3 [5.0%]). There were 3 serious treatment-related AEs 
observed (nausea, vomiting, and dehydration) in 1 patient who was aged 75 years. 
This patient completely recovered and was discontinued from the study. There 
were no deaths among the older patients during study participation. 
DISCUSSION 
Results of this subgroup analysis suggest hat older patients with persistent, 
moderate-to-severe, nonmalignant pain experienced significant decreases in 
pain and sleep interference, and increases in QOL were similar in comparison 
with younger subjects. Patients and clinicians reported increased satisfaction 
with P-ERMS compared with previous treatments. Of patients who completed 
the business reply card, 60% indicated that they remained on P-ERMS 4 weeks 
after study completion with continued improvement in satisfaction. Because 
responses on the business reply card were limited to those from patients who 
had completed the full study and had chosen to respond, they do not represent 
the full patient population. 
Over 70% of older patients in the study remained on QD administration for 
the duration of treatment. This might have been associated with the reduced 
volume of distribution and rate of morphine clearance in older patients, 14,1s and 
is consistent with reports that increased age is associated with a longer dura- 
tion of pain relief on opioids. 3,14 Alternately, it might be due to other factors 
affecting the pharmacodynamics of morphine 14 or due to characteristics of the 
pain experience or goals of treatment in older patients. 
The ability to dose with P-ERMS QD in most cases, and BID in the remaining 
cases, may be especially beneficial in older patients. AGS guidelines uggest 
that drug regimens be simplified as much as possible. 1The QD or BID adminis- 
tration schedule of P-ERMS, combined with the fact that it can be administered 
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without regard to meals, 25 provides simplification to both patients and care- 
givers, whether in the community or in residential facilities. Studies have demon- 
strated increased compliance when a regimen requires QD versus TID and QID 
administration, and BID versus QID. 31 Because the contents of the P-ERMS cap- 
sule can be sprinkled onto apple sauce or administered through a gastric feed- 
ing tube, patients might maintain the same medication regimen even if, as they 
age, they have difficulty swallowing whole capsules. 
Older patients in the study experienced typical opioid-related AEs. Consti- 
pation, the most frequent AE, was reported in 19.6% of older patients. Other 
studies of extended-release opioids in patients with a wide age distribution 
have demonstrated constipation rates of 27% to 45?/o. 32,33 AGS guidelines recom- 
mend a prophylactic bowel regimen and management plan when long-term opi- 
old treatment is initiated. 1The percentage of patients (29/148 [19.6%]) who 
withdrew from the trial due to an AE was comparable to other studies of 
extended-release opioids for chronic pain. 32'33 
The mean daily dose of P-ERMS was higher in older patients who dosed BID 
than in those who dosed QD. Yet, tolerability remained similar between the 
administration regimens. It is possible that the BID administration option 
served as a means of increasing the dose of P-ERMS for those who needed it to 
attain effectiveness without increasing the overall frequency of AEs. 
Due to the challenges of performing research in older populations, 22few stud- 
ies on opioids have been performed in patients aged >65 years. The KRONUS-MSP 
trial was not designed specifically to assess pain in older patients; however, the 
large sample size enabled identification and analysis of 148 older patients. 
While many patients demonstrated successful treatment outcomes, future pro- 
spective placebo-controlled studies should include outcome scales that have 
been validated in older patients, and should also address common concerns in 
older populations, such as cognitive function, ambulation, concomitant health 
issues, and cost. A study of longer duration would also be valuable to assess 
long-term effectiveness and safety. 
While patients experienced statistically significant pain reductions from 
baseline (pain level 7.4), the mean pain level at study completion was still 5.0. 
It is possible that continuation of the study period or adjustment of the compre- 
hensive pain management program might have yielded additional pain reduc- 
tion. However, it is not realistic to expect complete absence of pain for some 
persistent pain conditions. 1 It has been demonstrated that a 2-point decrease in 
pain scores on a 0 to 10 scale, which is equivalent o approximately a 30% 
decrease when entry criteria require a score _>4, is clinically important o pa- 
tients. 34 Therefore, the mean decrease of 2.4 points observed in this analysis, 
especially in patients with higher pain scores who had been receiving previous 
opioid medications, is noteworthy. 
Doses in the older patients were titrated from a mean (SD) daily starting 
dose of 40.5 (34.1) mg/d up to 77.0 (76.9) mg/d after 2 weeks. The significant 
increase in mean daily dose (P < 0.001) might be indicative that these older 
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patients were underdosed on their previous medications, as is often seen in the 
older population. 3 However, because investigators were instructed to initiate 
on a reduced starting dose of P-ERMS, the increase in mean daily dose might 
also reflect a return to therapeutic levels. 
Although patients were instructed to report their weekly use of rescue medi- 
cation and to bring the medication with them to each clinic visit, information 
on rescue medication use was not consistently recorded across the 202 study 
sites. Therefore, it was not possible to analyze rescue medication usage and the 
total daily dose of morphine. Monitoring of concomitant medications was also 
limited. Given that the study period lasted 4 weeks, it is unlikely that significant 
changes in concomitant medications would have been prevalent, but the possi- 
bility of bias does exist. 
While older patients had improvement in all outcomes with generally good 
tolerability, interpretation of the results is limited by the lack of a placebo arm. 
Inclusion of a placebo arm would have required patients to taper off current 
medication prior to receiving study medication, and would not have reflected 
clinical practice. The role of opioids is already recognized in managing chronic 
pain in older patients. ~Future studies comparing the efficacy, tolerability, and 
cost-benefit ratio of various formulations (active controls) might provide addi- 
tional information within an appropriate clinical framework. The withdrawal 
rate in this patient group (41.1%) also can be considered to be a limitation in 
interpreting the effectiveness of P-ERMS in the older patient population. This 
withdrawal rate, however, was similar to that reported with 4-week studies in 
mixed-age populations taking other extended-release morphine formulations. 33
Additional studies would be beneficial to assess the long-term use of P-ERMS 
and other opioids in the older population. 
CONCLUSIONS 
This subgroup analysis of a previously published study revealed that the older 
patients in that study who were receiving P-ERMS for persistent, moderate-to- 
severe, inadequately controlled, nonmalignant pain who completed the study 
attained significant improvements in pain, sleep, and QOL scores compared 
with baseline. Patient and clinician satisfaction with treatment increased signifi- 
cantly from baseline to study end. Older patients utilized significantly lower 
mean daily doses than younger patients, and >70% remained on a QD adminis- 
tration regimen for the duration of the study. 
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